Generating Advancements Through Longitudinal Analysis in X and Y Variations (GALAXY)

Recruiting

• Conditions: Sex Chromosome Aneuploidy

• Registration Number: NCT06373861
• Lead Sponsor: University of Colorado, Denver

Brief Summary

GALAXY is a registry research study that plans to learn more about individuals with X\&Y variations (also called sex chromosome aneuploidies) through collecting information from medical records.This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. The purpose of the GALAXY Registry is to collect and store this information with the overall goal to improve health outcomes in individuals with X\&Y variations and the care they receive.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-28
• Status Verified: 2024-04
• Study First Submitted: 2024-04-15
• Study First Submitted QC: 2024-04-15
• Last Update Submitted: 2024-04-15
• Study First Posted: 2024-04-18
• Last Update Posted: 2024-04-18
• Primary Completion: 2037-04
• Study Completion: 2037-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

1. Genetically-confirmed diagnosis of a sex chromosome aneuploidy condition
2. Any age
3. Any gender
4. Informed consent for individuals >18 years of age, parent/guardian permission for individuals <18 or proxy-consent from legally authorized representative if impaired decision making

Read More

Exclusion Criteria

a. Lack of documentation of genetic testing confirming SCA diagnosis

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health Conditions	From study start until condition observed, up to 15 years	Average number of chronic diagnoses per person

Secondary Outcome Measures

Name	Time	Method
Cardiometabolic diagnoses - prevalence of obesity	From study start until condition observed, up to 15 years	Prevalence of obesity is defined as the number of participants in the sample with obesity in their medical record out of the total sample. Obesity in pediatric populations is determined using BMI-for-age and obesity in adult populations is determined using BMI. BMI is calculated as the weight in kilograms divided by the height in meters squared.; Participants will be considered to have obesity if: * There is a diagnosis of obesity in the medical record in a clinical encounter, problem list, and/or past medical history; * For children 17 years and younger: there is an available growth chart/height/weight/other data necessary to calculate the BMI-for-age and the BMI-for-age is at or above the 95th percentile; * For adults 18 years and older: there is a BMI at or above 30 kg/m2 or the data necessary to calculate BMI and it is at or above 30 kg/m2
Cardiometabolic diagnoses-prevalence of hypertension	From study start until condition observed, up to 15 years	Prevalence of hypertension is defined as the number of participants in the sample with evidence of hypertension in their medical record out of the total sample. Evidence of hypertension includes: * Formal diagnosis of hypertension in a clinical encounter, problem list, and/or past medical history; * For children under 13 years old: a blood pressure reading at or above the 95th percentile for age, height, and sex; * For children between 13 and 17 years old: a blood pressure reading at or above 130/80 mmHg; * For adults 18 years or older: a blood pressure reading at or above 140/90 mmHg
Cardiometabolic diagnoses - prevalence of dyslipidemia	From study start until condition observed, up to 15 years	Prevalence of metabolic syndrome is defined as the number of participants in the sample with dyslipidemia in their medical record out of the total sample. Dyslipidemia will be defined as: * Diagnosis of dyslipidemia, hypertriglyceridemia, hypercholesterolemia in a clinical encounter, problem list, and/or past medical history; * Laboratory evidence of elevated total cholesterol, LDL, triglycerides, and/or low HDL for sex and age
Autoimmune diagnoses - prevalence of diabetes	From study start until condition observed, up to 15 years	Prevalence of diabetes is defined as the number of participants in the sample with evidence of hypertension in their medical record out of the total sample. Both type 1 and type 2 are included.
Prevalence of mental health diagnoses	From study start until condition observed, up to 15 years	Prevalence of mental health diagnoses is defined as the number of participants in the sample diagnosed with a mental health disorder by a clinician according to their medical record out of the total sample. This will be determined by a diagnosis of any of the following in a clinical encounter, problem list, and/or past medical history: * Depression; * Anxiety; * Mood disorder NOS; * Psychotic disorder; * Attention-deficit/hyperactivity disorder (ADHD); * Autistic disorder
Autoimmune diagnoses - prevalence of hypothyroidism and of hyperthyroidism	From study start until condition observed, up to 15 years	Prevalence of hypothyroidism is defined as the number of participants in the sample with evidence of hypertension in their medical record out of the total sample.

Trial Locations

Locations (1)

Children's Hospital Colorado; 🇺🇸 Aurora, Colorado, United States